Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine in Post-CAR-T Relapsed/Refractory DLBCL or HGBCL
NCT06918912Phase 2Recruiting
- Sponsor
- Humanitas Research Hospital
- Start
- Jun 2023
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) and high grade B-cell lymphoma (HGBCL), sponsored by Humanitas Research Hospital. Primary endpoint: Overall Response Rate. Started Jun 2023; status: recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT06918912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918912.